PharmEasy Valuation Drops From $5.6 Billion To $456 Million
The Indian online pharmacy, once valued at $5.6 billion, has seen its worth drop to $456 million, according to a December 27, 2024 report by ISN.
Investor Janus Henderson slashed the value of its 12.9 million shares from $9.4 million to $766,043, marking a 92% valuation fall in PharmEasy valuation.
PharmEasy’s parent, API Holdings, reported FY24 losses of Rs 2,533 crore, with revenue down 15% to Rs 5,664 crore.
Despite raising $216 million in April 2024 and cutting losses by 50%, the startup, known for its $600 million Thyrocare acquisition, is banking on a 2025 IPO to recover.
Read More at Stockify
